Overview

Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder

Status:
Terminated
Trial end date:
2020-09-04
Target enrollment:
Participant gender:
Summary
This is a phase II, randomized, single-blind, placebo-controlled study to examine whether cariprazine (1.5 or 3 mg/d) 1) alters brain and/or behavioral responses to probes of reward and inhibition and 2) decreases cocaine use in individuals with cocaine use disorder. Subjects will be tested as inpatients during fMRI sessions. After the 2-week inpatient/medication induction phase, study medication will continue for 8 outpatient weeks, during which time cocaine use will be tracked. Subjects will be monitored during a 4-wk followup phase thereafter.
Phase:
Phase 2
Details
Lead Sponsor:
Anna Rose Childress
Anna Rose Childress, Ph.D.
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Cariprazine
Cocaine